Advertisement

Topics

Valchlor (mechlorethamine)

23:57 EST 12th December 2018 | BioPortfolio

VALCHLOR, a gel which is applied topically once a day, is an alkylating drug indicated to treat patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) who have received prior skin-directed therapy. VALCHLOR is an orphan drug that was acquired by Actelion US Holding Company, a subsidiary of Actelion Ltd., on September 18, 2013 as part of a merger with Ceptaris Therapeutics, Inc. VALCHLOR is distributed in the US by Accredo Specialty Pharmacy.

VALCHLOR (mechlorethamine) gel 0.016% is an alkylating drug indicated for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy. VALCHLOR is a gel which is applied topically once a day. Mechlorethamine, commonly known as nitrogen mustard, is a chemotherapeutic agent previously approved for intravenous treatment of mycosis fungoides, the most common type of cutaneous T-Cell lymphoma. Mechlorethamine is one of the suggested skin-directed treatment regimens for early-stage MF-CTCL according to the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®)[1]. VALCHLOR is the first and only FDA-approved topical formulation of mechlorethamine.

For more information and full prescribing information visit www.valchlor.com

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Valchlor (mechlorethamine) market research data and corporate reports here